How do you counsel a patient who inquires about the role of a GLP-1 receptor agonist as a treatment for mast cell activation syndrome (MCAS)?

While there is evidence of symptom improvement in a recent case series of MCAS patients on GLP-1 agonists, it is not sufficient by itself AND IT DEPENDS ON WHETHER OTHER APPROACHED HAVE BEEN EXXAUSTED. ONE should pay careful attention to the patient's BMI and weigh the potential benefits against the...